Cardiometabolic diseases are a leading cause of morbidity and mortality in both the developing and developed countries. Led by Dr. Roshni Singaraja, our group is interested in translational research with a focus on identification and functional characterization of pathways involved in cardiometabolic disease.
The neurodegenerative diseases (NDD) laboratory, led by Dr. Mahmoud Pouladi, focuses on understanding how discrete genetic factors contribute to the development of NDD.
Led by Dr. Liam Brunham, the PGx laboratory focuses on understanding how genetic information can be used to predict, diagnosis and treat disease.
Led by Dr Marie Loh, the Integrative Omics group focuses on the identification of biomarkers and mechanisms underlying cardiometabolic diseases and associated disturbances, with a specific interest in transethnic studies. The group aims to develop new strategies for disease prediction, prevention and treatment through the integrative analysis of high-throughput omics data across different platforms (array- and NGS- based).
Led by Dr.Chester Drum, the clinical trial innovation lab focuses on new ways of scientific engagement with real world patients. Treating patients as partners in discovery, the lab uses cutting edge technology and protocol design to maximise the information from clinical investigations.
Cardiometabolic diseases are a leading cause of morbidity and mortality in both the developing and developed countries. Led by Dr. Roshni Singaraja, our group is interested in translational research with a focus on identification and functional characterization of pathways involved in cardiometabolic disease. Our aim is to identify novel genes, validate the novel genes utilising human genetic association studies, and bridge the gap between the human association studies and functional mechanisms utilizing human investigative medicine studies, animal models and in vitro studies relevant to the disease states of diabetes mellitus, atherogenic dyslipidemia and cardiovascular disease.
The neurodegenerative diseases (NDD) laboratory, led by Dr. Mahmoud Pouladi, focuses on understanding how discrete genetic factors contribute to the development of NDD. Our aim is to define key disease processes underlying neurodegenerative disorders and to develop novel therapeutic approaches for intervention.
Led by Dr. Liam Brunham, the PGx laboratory focuses on understanding how genetic information can be used to predict, diagnosis and treat disease. We are particularly focused on identifying genetic variation that predicts response to medications and understanding molecular mechanisms of drug toxicity.
Led by Dr Marie Loh, , the Integrative Omics group focuses on the identification of biomarkers and mechanisms underlying cardiometabolic diseases and associated disturbances, with a specific interest in transethnic studies. The group aims to develop new strategies for disease prediction, prevention and treatment through the integrative analysis of high-throughput omics data across different platforms (array- and NGS- based).
Led by Dr.Chester Drum, the clinical trial innovation lab focuses on new ways of scientific engagement with real world patients. Treating patients as partners in discovery, the lab uses cutting edge technology and protocol design to maximize the information from clinical investigations. Of particular interest is how small volume biosampling of nonrandomised, case-control cohorts can aid in more efficient regulatory approval and more rapid clinical acceptance of new diagnostics. Biomarkers are both discovered and validated using a dedicated quantitative LCMS facility, while incorporating novel materials and devices sourced from the broader Singapore research community.